Tomokazu Sazuka
Overview
Explore the profile of Tomokazu Sazuka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
236
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Hara S, Fukuokaya W, Miki J, Taoka R, Saito R, Matsui Y, et al.
Int J Urol
. 2025 Feb;
PMID: 39907200
Objective: To examine the association between substaging and outcomes following radical cystectomy (RC) in patients with stage III bladder cancer. Methods: We conducted a retrospective observational study using nationwide data...
3.
Kikuchi H, Osawa T, Matsushita Y, Kojima T, Sazuka T, Hatakeyama S, et al.
Jpn J Clin Oncol
. 2025 Feb;
PMID: 39893579
Objective: To validate multiple prognostic models in metastatic renal cell carcinoma patients who received second-line axitinib following first-line nivolumab plus ipilimumab therapy. Methods: Five prognostic models (ACL, albumin, C-reactive protein,...
4.
Nozumi K, Sakamoto S, Zhao X, Pae S, Tamura T, Taguchi K, et al.
Int J Urol
. 2024 Dec;
PMID: 39740093
Objectives: To evaluate the success rate of shock wave lithotripsy and identify predictors of stone-free status after shock wave lithotripsy for ureteral stones, focusing on the impact of stones remaining...
5.
Yamada Y, Sato K, Sakamoto S, Tsujino T, Saito S, Nishimura K, et al.
Int J Clin Oncol
. 2024 Dec;
30(3):539-550.
PMID: 39656401
Background: This study investigated the characteristics of prostate-specific antigen (PSA) dynamics when androgen receptor signaling inhibitor (ARSI), or vintage agent (bicalutamide) was used for patients with metastatic hormone-sensitive prostate cancer...
6.
Mori K, Numakura K, Matsushita Y, Kojima T, Osawa T, Sazuka T, et al.
Cancer Sci
. 2024 Nov;
116(2):444-452.
PMID: 39550694
Nivolumab plus ipilimumab (NIVO+IPI) has a long-term response rate of 30% for patients with metastatic renal cell carcinoma (mRCC). However, 20% of patients develop primary resistant disease (PRD) to NIVO+IPI...
7.
Sato K, Sazuka T, Arai T, Sato H, Kanesaka M, Ando K, et al.
BJUI Compass
. 2024 Oct;
5(10):950-956.
PMID: 39416750
Objectives: Renal cell carcinoma (RCC) is shown to have a tendency for late recurrence, occurring 5 or more years after curative surgery. Imaging diagnosis is required for follow-up, and there...
8.
Kato M, Taoka R, Miki J, Saito R, Fukuokaya W, Matsui Y, et al.
Int J Clin Oncol
. 2024 Oct;
29(12):1937-1945.
PMID: 39379757
Background: Radical cystectomy in women generally includes the removal of the uterus, ovaries, and anterior vaginal wall, but the criteria for reproductive organ sparing are not clear. Methods: A total...
9.
Fukuokaya W, Miki J, Taoka R, Saito R, Matsui Y, Hatakeyama S, et al.
Int J Urol
. 2024 Sep;
31(12):1414-1422.
PMID: 39291802
Objectives: This study aims to develop a prognostic model that estimates the post-operative risk of cancer-specific mortality in patients with bladder cancer who underwent radical cystectomy (RC). Methods: We analyzed...
10.
Isoda B, Kandori S, Sazuka T, Kojima T, Nitta S, Shiga M, et al.
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000552
Combination therapy of nivolumab and ipilimumab (NIVO + IPI) for metastatic renal cell carcinoma (mRCC) has shown efficacy, but approximately 20% of patients experience disease progression in the early stages...